Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

R&D Systems™ 1-Azakenpaullone
SDP

Catalog No. RD10188017 Shop All Novus Products
Change view
Click to view available options
Quantity:
10 mg
50 mg
2 product options available for selection
Product selection table with 2 available options. Use arrow keys to navigate and Enter or Space to select.
Catalog No. Quantity
RD10188017 50 mg
RD10188004 10 mg
Use arrow keys to navigate between rows. Press Enter or Space to select a product option. 2 options available.
2 options
Catalog No. RD10188017 Supplier R&D Systems™ Supplier No. 3673/50

Customers require a valid business account associated to their profile to access pricing and ordering options.

missing translation for 'validMainframeMsg'

A Tocris product, part of R&D Systems.

1-Azakenpaullone is a potent and selective glycogen synthase kinase 3 (GSK-3) inhibitor (IC50 = 18 nM). It displays selectivity index (SI) of 111 and 233 over CDK1 and CDK5, respectively. 1-Azakenpaullone stimulates growth and replication of β-cells in vitro (rat islets) and alleviates glucolipotoxicity in INS-1 β-cells. It displays mitogenic effects on rat β-cells comparable with those of incretin hormone GIP. In combination with TTNPB (Cat. No. 0761) and WS 6 (Cat. No. 7791), 1-Azakenpaullone can be part of a chemical cocktail used for induction and long-term maintainance in vitro of totipotent stem cells (TotiSCs) from mouse pluripotent stem cells (PSCs).

Specifications

Chemical Name or Material 9-Bromo-7,12-dihydropyrido[3',2':2,3]azepino[4,5-b]indol-6(5H)-one
CAS 676596-65-9
Quantity 50 mg
Product Line Tocris
Target GSK-3 Inhibitors
Molecular Formula C15H10BrN3O
Purity 98%
Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.